Monocytes are critical to the pathogenesis of inflammatory bowel disease (IBD) as they infiltrate the mucosa and release cytokines that drive the inflammatory response. Ursodeoxycholic acid (UDCA), a naturally-occurring bile acid with antiinflammatory actions, has been proposed as a potential new therapy for IBD.
Introduction
Inflammatory Bowel Diseases (IBD), comprised of Ulcerative Colitis (UC) and
Crohn's Disease (CD), are common chronic inflammatory disorders of the intestinal tract. While the pathogenesis of IBD is still not fully understood, it is now widely accepted to involve genetic, environmental, and immunological factors that ultimately lead to dysregulation of innate barrier function (3) . Current treatments for IBD employ salicylates, immunosupressants, corticosteroids, and biologics in order to first induce, and then maintain remission (5) . However, while such treatments are effective in some patients, they are often limited by their lack of efficacy, cost, and occurrence of side effects. Despite intense research activity in the area, few new treatments for IBD have emerged over the past decades and new approaches are constantly being sought.
In recent years there has been increased interest in the potential for targeting innate intestinal barrier function for treatment of IBD. Innate barrier function is critical for normal intestinal health as it maintains separation of the body from the luminal contents, excluding the entry of harmful substances, such as bacteria and their toxins, to the mucosa. The innate barrier consists of the physical barrier posed by the epithelial layer, secreted factors, such as mucus, immunoglobulins, defensins, and cytokines, and myeloid immune cell populations present within the mucosa (24, 47) .
Many aspects of epithelial barrier are altered in conditions of IBD (20, 31) , and that dysregulated innate immune function is a primary contributor to the progression of the disease is beyond doubt. Both UC and CD are characterised by the accumulation of inflammatory macrophages and dendritic cells within the mucosa.
When the epithelial barrier is breached, these cells act as the first line of defence performing important roles, including phagocytosis, production of pro-and antiinflammatory mediators and cytokines, antigen presentation, and ultimately recruitment of the adaptive immune response (24) . Key to initiating and driving these events is the infiltration of monocytes, from which macrophages and dendritic cells are derived, from the circulation to the mucosa. Under the influence of chemokines produced by the epithelium, circulating monocytes increase their surface expression of the gut homing receptor, CCR9 (27) , thereby targeting them to the mucosa and upregulating the expression of pro-inflammatory cytokines (15, 21, 42) . In turn, such pro-inflammatory mediators (e.g., interleukin-8; IL-8) induce the influx of neutrophils and eosinophils, thereby further driving the inflammatory response (41, 46) . The importance of monocytes in the development of IBD is evidenced by studies showing that their recruitment to the mucosa is necessary for the progression of inflammatory disease in animal models and that treatments which reduce monocyte numbers, such as apheresis, are effective in alleviating intestinal inflammation in patients (38, 44) . Thus, given their central role in the initiation and maintenance of inflammatory responses, monocytes present an excellent target for the development of new therapies for IBD.
Originally identified in bear bile, ursodeoxycholic acid (UDCA) is a naturally-occurring secondary bile acid, produced in the colon by bacterial metabolism of the primary bile acid, chenodeoxycholic acid (CDCA). While quantitative and qualitative changes in the colonic bile acid pool are associated with the pathogenesis of IBD (10, 11, 25) , UDCA is unique among the family of bile acids as it has long been appreciated to have therapeutic actions. As a component of bear bile, it has been used for centuries in Traditional Chinese Medicine to treat a range of ailments, and more recently in Western medicine to treat liver inflammation and cholestasis (12, 32) . UDCA is considered to be a very safe drug and unless used at high doses has few side effects. In addition to its FDA-approved uses for liver disorders, UDCA is currently under investigation for a range of extraintestinal conditions, including neurological, ocular, and cardiovascular diseases (45) . The distinct mechanisms underlying the wide-ranging therapeutic effects of UDCA are still poorly defined but they are believed to the anti-inflammatory and cytoprotective actions of the bile acid (35, 45) .
The biological actions of UDCA have been mostly studied in the liver, where it has been shown to have immunomodulatory and anti-apoptotic effects, and to prevent cytokine release from hepatocytes (1, 34, 36) . Interestingly, several studies have shown that UDCA also exerts protective actions in animal models of intestinal inflammation, effects which were associated with reduced levels of mucosal cytokines, nitric oxide, and prevention of epithelial apoptosis (8, 22, 23, 28) .
However, while UDCA shows excellent promise for development into a new therapy for IBD, there is still little known of its actions on monocyte function and in the current study we set out to begin to address this gap in our knowledge. Using primary monocytes isolated from humans and cultured cells in vitro, we assessed the effects of UDCA on cytokine secretion in response to stimulation with either the inflammatory mediator, TNF, or the bacterial endotoxin, lipopolysaccharide (LPS).
We used IL-8, as a marker of monocyte-derived cytokine release, as it has been well-established as a key player in driving IBD pathogenesis.
Methods
Chemicals: UDCA (sodium salt) was obtained from Santa Cruz Technologies and stock solutions were prepared using deionised H 2 O. LPS (E.coli, K235 strain) and TNF were obtained from Sigma Chemical Co. (Poole, Dorset, UK). BMS-345541 was obtained from Merck Millipore (Darmstadt, Germany). SB203580 and all antibodies were obtained from Cell Signalling Inc (Danvers, MA). All other reagents were of analytical grade.
Cell Culture: U937 monocytes were maintained in a humidified atmosphere, containing 5% CO 2 at 37°C. The cells were cultured in 75 cm 3 found that co-treatment with UDCA (100 M) significantly reduced TNF-stimulated IL-8 release from 2,343 ± 282 to 1,684 ± 243 (n = 3; p ≤ 0.01), but had no effect on that induced by LPS-driven IL-8 release (n = 3) (Figures 1 A-B ).
The effect of UDCA on a well-established in vitro model of monocytes, U937 cells, was also examined. Similar to our findings in primary monocytes, both TNF and LPS induced increases in IL-8 release, although LPS was not as potent as it was in primary monocytes. IL-8 release from TNF and LPS-stimulated cells increased from 755 ± 234 pg/mL to 4356 ± 818 and 6135 ± 2112 pg/mL, respectively.
SimilarFurthermore, similar to its effects in primary monocytes, UDCA significantly attenuated TNF-stimulated IL-8 release. UDCA was most effective at the highest concentration tested, 100 M, reducing TNF-driven IL-8 release from 4356 ± 818 to 1880 ± 374 pg/ml (n = 5; p ≤ 0.001) (Figure 2A ). However, also similar to our findings in primary cells, UDCA had no effect on LPS-stimulated IL-8 release ( Figure 2B ). All concentrations of UDCA inhibited basal secretion of IL-8 ( Figure 2C ) but were not toxic, as determined by measurements of LDH release ( Figure 2D ). Thus, given that U937 cells recapitulate our findings in primary monocytes, these cells were used in all subsequent experiments.
Next, we carried out experiments to determine if the effects of UDCA on IL-8 secretion could be due to alterations in mRNA expression. In these experiments we carried out PCR on cDNA prepared from RNA isolated from monocytes treated with TNF or LPS, either in the absence or presence of UDCA. We found that the bile acid attenuated both basal and TNF-induced increases in IL-8 mRNA expression, but was without effect on responses to LPS (Figure 3 ).
Effects of UDCA on IL-8 secretion are independent of p38 MAP kinase. Having demonstrated differential effects of UDCA on TNF and LPS-induced IL-8 release from monocytes, we next carried out experiments to investigated signalling mechanisms that may be involved. Since the p38 MAPK pathway has been previously linked to driving IL-8 release from monocytes, we first focussed on investigating the potential involvement of this pathway. We found that treatment with either LPS or TNF increased phosphorylation of p38 MAPK in U937 monocytes ( Figure 4A-B) . Interestingly, treatment with a specific p38 MAPK inhibitor, SB203580 (10 µM), attenuated only LPS-driven IL-8 release without altering TNF-induced responses ( Figure 4C-D) . UDCA did not inhibit either TNF  or LPS-induced phosphorylation of p38 MAPK and even tended to increase this response to LPS ( Figure 4A-B) .
UDCA specifically attenuates TNF-induced activation of NFB. Next, we investigated a potential role for NFB, an integral signalling protein thatwhich has been shown to mediate IL-8 release in response to LPS and TNF in other systems (13, 16) , as a target for the actions of UDCA on cytokine release from monocytes.
Thus, we first investigated the effects of UDCA on NFB activation in U937 cells, using phosphorylation of the p65 subunit as a marker of NFB activation. We found that both TNF and LPS induced 5.7 ± 0.6 and 2.1 ± 0.4 fold increases in phosphorylation of p65, a reliable marker of NFB activation, in U937 cells, respectively. Interestingly, UDCA co-treatment specifically attenuated TNF-induced p65 phosphorylation of p65 to 2.8 ± 1.2 fold (n = 3; p ≤ 0.05), while it had no effect on responses to LPS (n = 4) ( Figure 5A-B) . In further experiments, we found that inhibition of NFB with the specific inhibitor, BMS-345541 (10 µM UDCA inhibits TNF-induced phosphorylation of TRAF2. To further elucidate how UDCA might exert its differential effects on TNF and LPS-induced NFB activation, we next examined TRAF2 activation. TRAF2 is an adaptor protein that, upon TNF stimulation, is recruited to the TNFR and becomes phosphorylated, ultimately leading to activation of downstream effectors, including NFB (9) . As expected, we found that TNF treatment induced a rapid phosphorylation of TRAF2, whereas LPS had no effect ( Figure 6A ). Furthermore, when cells were co-treated with UDCA phosphorylation of TRAF2 in response TNF was significantly inhibited ( Figure 6B ).
Discussion
A growing body of evidence suggests that UDCA may be useful in treatment of intestinal inflammation. In particular, it has been repeatedly shown that UDCA, or its taurine-conjugate, tauroursodexoycholic acid (TUDCA), is protective in animal models of intestinal inflammation and that such actions may be attributed to prevention of epithelial apoptosis and inhibition of mucosal cytokine accumulation (23, 28) . Our current studies suggest that inhibition of mucosal monocyte function may also have a role to play in mediating the anti-inflammatory actions of the bile acid.
TNF and IL-8 are well-established as 2 of the primary cytokines driving mucosal inflammation in IBD (18) . Inflammatory cells within the mucosa have been previously identified as the main source of IL-8 in IBD (2, 7), while TNF and LPS are both known to potently stimulate release of the cytokine from monocytes. In turn, monocyte-derived IL-8 acts as a potent chemoattractant to other innate myeloid cells, such as neutrophils, leading to increased proinflammatory cytokine production and perpetuation of inflammation. This vicious cycle of inflammation underlies the mucosal damage that occurs in IBD and strategies that dampen its activity should be of use in disease treatment. Here, we found that UDCA inhibits TNF induction of IL-8 secretion from monocytes. The effects of UDCA were apparent at the level of IL-8 mRNA expression, suggesting inhibition of cytokine expression at the level of gene transcription is likely involved. Furthermore, we found that the effects of UDCA on IL-8 release from monocytes were specific to TNF, since the bile acid did not alter secretion of the cytokine in response to the bacterial endotoxin, LPS.
Further investigation into the signaling mechanisms involved suggested that the differential effects of UDCA on TNF and LPS-induced IL-8 production is likely due to the distinct mechanisms by which these agonists act on monocytes. LPS exerts its actions through binding to TLR4 and its co-receptor, CD14 (17, 37) , whereas TNF acts through TNFRs. While both receptors activate both NFB and p38 MAPK in monocytes, these signaling pathways appear to have distinct roles in mediating IL-8 secretion in response to the different agonists. We found that a selective p38 MAPK inhibitor, SB203580, significantly attenuated LPS-induced IL-8 secretion, without altering that in response to TNF. In contrast, inhibition of NFB with BMS-345541 reduced IL-8 production in response to LPS, while abolishing responses to TNF.
Together, these data suggest that while LPS-induced IL-8 release from monocytes is mediated by pathways involving both p38 MAPK and NFB, responses to TNF do not involve p38 MAPK but are more dependent on NFB. Interestingly, we also found that while treatment with UDCA prevented activation of NFB in response to TNF, as measured by phosphorylation of the NFB p65 subunit, it was without effect on LPS-induced NFB activation. Thus, our data suggests that the specificity of UDCA for inhibiting TNF-induced IL-8 secretion likely stems from inhibition of an upstream component that is distinct to the TNFR/NFB signaling pathway. With this in mind, we investigated the possibility that TRAF-2 may be a target of UDCA action in monocytes. TRAF-2 is a signaling protein that is recruited to activated TNFR and which is a critical regulator of downstream signaling, including NFB activation (9) . In our current studies, we found that TNF but not LPS, treatment of monocytes induced phosphorylation of TRAF-2 and, in support of our hypothesis, UDCA significantly inhibited this effect.
While the current study is the first to demonstrate an inhibitory effect of UDCA on TNF-induced cytokine release from monocytes, previous studies have shown its lack of effects on LPS-induced cytokine production (4, 14) . Indeed, previous studies have also reported differential actions of UDCA compared to other colonic bile acids on multiple aspects of monocyte function. For example, while DCA and CDCA inhibit cytokine release and the pro-coagulant activity of LPS-stimulated monocytes, UDCA is without effect (6, 14) . Such differential actions imply strict structure-activity requirements for the actions of bile acids on different aspects of monocyte function.
This likely reflects different potencies of different bile acids at bile acid receptors. For example, in contrast to the actions of UDCA shown here, agonists of the cell surface bile acid receptor, TGR5, have been shown to inhibit LPS-induced cytokine release from monocytes (26) . This, along with previous reports of the low potency of UDCA at TGR5 (19) , suggests it is unlikely that this receptor mediates effects of the bile acid reported in the current studies, A role for FXR also seems unlikely since it has been previously shown not to be expressed in U937 cells (29) , a finding confirmed by our own preliminary studies (data not shown) Other possibilities for how UDCA could induce responses in monocytes include activation of the pregnane x receptor or the glucocorticoid receptor, both of which have been reported to be activated by UDCA in other systems (39, 40, 48) and both of which have been shown to be protective in animal models of intestinal inflammation (33, 43) . This question of how UDCA triggers anti-inflammatory responses in monocytes is the subject of ongoing work in our research group.
In summary, the results described in this paper illustrate for the first time, the ability of UDCA to specifically inhibit TNF-induced IL-8 release from monocytes. Given the central role that these cytokines play in the pathogenesis of IBD, one would expect that such actions of the bile acid would dampen mucosal inflammation in vivo. Cells were treated with LPS (1 g/mL) in the presence of UDCA (100 M) for 1 hr (n = 4). U937 monocytes, seeded at a density of 50,000 cells/well in 96 well plates were pretreated with the specific NFB inhibitor, BMS-345541 (10 M) for 1 hr prior to treating with C) TNF (5 ng/mL; n = 4) or D) LPS (1 g/mL; n = 5) for 24 hrs.
Samples of the incubation media were then taken and assayed for IL-8 by ELISA.
Data represent the mean ± SEM for a series of n experiments. Statistical analyses were performed using ANOVA followed by the Student Newman Keul's post-test (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001). 
